PRISM MarketView

Viking Therapeutics Shares Start Year at $18 and Now Trade For $72: Here’s Why the Company is Up Over 300% YTD

New York, October 24, 2024 - PRISM MarketView - Viking Therapeutics (VKTX) was a meek stock when the year started that traded around $18 and today as the stock boosts a 21% return on its recent Q3 earnings is trading around $75. So how did this PRISM Weight Loss Index co...

24 October 2024

LifeMD Launches TestoRx, a New Direct-to-Consumer Testosterone Replacement Therapy

New York, October 24, 2024 - PRISM MarketView - Just ahead of Movember, the annual movement to raise awareness of men’s health issues, LifeMD, Inc. (Nasdaq: LFMD) has introduced TestoRx, a new testosterone replacement therapy (TRT) offering through its Rex MD men’s healt...

24 October 2024

BranchOut Food Projects $15M Run Rate and Positive Cash Flow in Q1 2025 Amid Surge in New Orders

New York, October 24, 2024 - PRISM MarketView - BranchOut Food Inc. (NASDAQ: BOF) shares are trading up 8% after announcing several milestones that are projected to drive growth and profitability in 2025. With the launch of its production facility in Peru and a rise in m...

24 October 2024

Ocuphire Pharma Acquires Opus Genetics, Expanding Gene Therapy Pipeline and Extending Cash Runway into 2026

Transformational Merger Renames Combined Entity to Opus Genetics, Strengthening Position in Inherited Retinal Disease and Ophthalmic Therapeutics

24 October 2024

Sunrun Partners with Orange and Rockland to Get New York’s Largest Residential Power Plant on the Grid

New York, October 23, 2024 - PRISM MarketView - Sunrun (RUN), the leading provider of clean energy subscription services in the U.S., and Orange and Rockland Utilities, Inc., a subsidiary of Consolidated Edison, Inc. (ED), one of the nation’s largest investor-owned energ...

23 October 2024

Looking Good! OKYO Pharma Doses First Patient in Phase 2 Trial for Corneal Neuropathic Pain, Shares Rise 15%

New York, October 23, 2024 - PRISM MarketView - OKYO Pharma (NASDAQ: OKYO) has announced the dosing of the first patient in its Phase 2 clinical trial of OK-101, a novel, non-opioid treatment for neuropathic corneal pain (NCP), marking a significant milestone in the deve...

23 October 2024

PRISM AdTech & Media: Magnite and Disney are Still Making Magic As They Extend Partnership

New York, October 23, 2024 - PRISM MarketView - The largest independent sell-side advertising platform Magnite (MGNI), has announced the extension of its six-year partnership with Disney (DIS) for an additional two years. Maginite has been Disney’s preferred supply-side ...

23 October 2024

Athira Pharma to Present Phase 2/3 LIFT-AD Trial Results at CTAD 2024; Shares Up 17%

New York, October 22, 2024 - PRISM MarketView - Athira Pharma, Inc. (Nasdaq: ATHA), a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, announced that it will present the results of its Phase 2/3 LIFT-AD trial of fo...

22 October 2024

Annexon Presents Promising Phase 2 Data for ANX007 in Dry AMD at AAO 2024

New York, October 22, 2024 - PRISM MarketView - Annexon, Inc. (Nasdaq: ANNX) presented new findings from its Phase 2 ARCHER study for ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD) at the American Academy of Ophthalmology (AAO) 2024 m...

22 October 2024

Veritone Is ‘VERI’ Serious About Accelerating AI Business; Sells Media Agency for Up to $104M

New York, October 22, 2024 - PRISM MarketView - PRISM AdTech and Media Index company Veritone (VERI), has announced the sale of its media agency, Veritone One, LLC to Insignia Capital Group as it continues to focus on being a leader in human-centered enterprise AI soluti...

22 October 2024